
Amgen (NASDAQ: AMGN) has announced the results of a Phase III trial, published in The Lancet, which shows that Nplate …
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine

